CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
影响接受 CAR-T 治疗或干细胞移植患者心理症状管理的当前挑战
英文原题：Present challenges impacting the management of psychological symptoms in patients receiving CAR-T therapy or stem cell transplantation.
查看英文原题
Present challenges impacting the management of psychological symptoms in patients receiving CAR-T therapy or stem cell transplantation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们建议进一步研究肿瘤治疗与姑息治疗团队整合模式及其疗效。
研究思路结论见上方概要
背景
造血干细胞移植（HSCT）和CAR-T 细胞疗法在血液系统恶性肿瘤的治疗中至关重要。HSCT长期以来一直是这些疾病的主要治疗手段，而CAR-T 是一种较新的疗法，有可能改变治疗格局。这两种细胞疗法都需要大量的时间和资源，这给患者带来了与其他肿瘤治疗形式所不同的压力。 涵盖领域：在本综述中，我们讨论了与HSCT和CAR-T 相关的心理症状及其管理的现有知识状况。此外，我们还讨论了用于开展此类研究的患者报告结局（PROs）模型。我们在PubMed上使用包括“palliative care、palliative care integration、hematologic malignancy、patient reported outcome、psychological care和生活质量”在内的关键词进行了文献检索。我们纳入了2025年4月1日之前发表的论文。
展开英文摘要原文
INTRODUCTION: Hematopoietic stem cell (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy are crucial in the treatment of hematologic malignancies. While HSCT has been long established as a mainstay of the treatment of these diseases, CAR-T is a newer therapy with the potential to change the treatment landscape.
Both cellular therapies are time and resource intensive, which has put stressors on patients that are unique from those associated with other forms of oncologic treatment. AREAS COVERED: In this review, we discuss the current state of knowledge of psychological symptoms associated with HSCT and CAR-T and their management.
In addition, we discuss the models of patient reported outcomes (PROs) used to perform this research.
We performed a literature review on PubMed using keywords including 'palliative care, palliative care integration, hematologic malignancy, patient reported outcome, psychological care, and quality of life.'
We included papers published before 1 April 2025. EXPERT OPINION: We propose further investigations into integrated models of oncologic and palliative care teams and their efficacy.
论文信息
- 作者
- Feng A、Gottam M、Santivasi WL、LeBlanc TW
- 单位
- Department of Medicine, Duke University School of Medicine, Durham, NC, USA.United States
- 文献类型
- 综述
- 期刊
- Expert review of pharmacoeconomics & outcomes research2025 Dec
- 原文标识
- PubMed 41055294 · DOI 10.1080/14737167.2025.2572317